A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma

British Journal of Dermatology

Volumn 178, Issue 1, 2018, Pages 265-269

  Wolner, Z J ^a   Marghoob, A A ^a   Pulitzer, M P ^a   Postow, M A ^a,b   Marchetti, M A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURGERY; CASE REPORT; CLINICAL ARTICLE; DRUG SAFETY; EPILUMINESCENCE MICROSCOPY; EYEBROW; EYELASH; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LENTIGO; MACULAR SEBORRHOEIC KERATOSIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; PAPILLARY DERMIS; PHOTOGRAPHY; PIGMENTED NEVUS; PRIORITY JOURNAL; SCALP; SEBORRHEIC KERATOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN COLOR; SKIN DEFECT; SKIN EXAMINATION; THREE DIMENSIONAL IMAGING; TREATMENT DURATION; WIDE EXCISION; LIVER TUMOR; MELANOMA; PIGMENT DISORDER; SECONDARY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PIGMENTATION DISORDERS; SKIN NEOPLASMS;

EID: 85030237424     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15354     Document Type: Article

References (15)

1. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015; 37:764–82.
2. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375–91.
3. Sibaud V, Meyer N, Lamant L et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28:254–63.
4. Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60:12–25.
5. Hwang SJ, Carlos G, Wakade D et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74:455–61.
6. Rodic N, Anders RA, Eshleman JR et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res 2015; 3:110–5.
7. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37.
8. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica 1991; 183:239–45.
9. Teulings HE, Limpens J, Jansen SN et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33:773–81.
10. Hua C, Boussemart L, Mateus C et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152:45–51.
11. MacKie RM, English J, Aitchison TC et al. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 1985; 113:167–74.
12. Marghoob AA, ed. Nevogenesis: Mechanisms and Clinical Implications of Nevus Development. Berlin: Springer, 2012.
13. Groesser L, Herschberger E, Landthaler M, Hafner C. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis. Br J Dermatol 2012; 166:784–8.
14. Shi VJ, Rodic N, Gettinger S et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016; 152:1128–36.
15. Melanoma Research Foundation. Melanoma Patients Information Page. Disappearing moles after immunotherapy. Available at: https://www.melanoma.org/find-support/patient-community/mpip-melanoma-patients-information-page/disappearing-moles-after (last accessed 26 June 2017).